BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

49 related articles for article (PubMed ID: 9205060)

  • 1. Comparisons of CYP2D messenger RNA splice variant profiles in human lung tumors and normal tissues.
    Huang Z; Fasco MJ; Spivack S; Kaminsky LS
    Cancer Res; 1997 Jul; 57(13):2589-92. PubMed ID: 9205060
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alternative splicing of CYP2D mRNA in human breast tissue.
    Huang Z; Fasco MJ; Kaminsky LS
    Arch Biochem Biophys; 1997 Jul; 343(1):101-8. PubMed ID: 9210651
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of cytochromes P450 in human breast tissue and tumors.
    Huang Z; Fasco MJ; Figge HL; Keyomarsi K; Kaminsky LS
    Drug Metab Dispos; 1996 Aug; 24(8):899-905. PubMed ID: 8869826
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Presence of splice variant forms of cytochrome P4502D1 in rat brain but not in liver.
    Chinta SJ; Pai HV; Ravindranath V
    Brain Res Mol Brain Res; 2005 Apr; 135(1-2):81-92. PubMed ID: 15857671
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inter-individual variation of several cytochrome P450 2D6 splice variants in human liver.
    Denson J; Wu Y; Yang W; Zhang J
    Biochem Biophys Res Commun; 2005 May; 330(2):498-504. PubMed ID: 15796910
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quantification of CYP2B7, CYP4B1, and CYPOR messenger RNAs in normal human lung and lung tumors.
    Czerwinski M; McLemore TL; Gelboin HV; Gonzalez FJ
    Cancer Res; 1994 Feb; 54(4):1085-91. PubMed ID: 8313365
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetic variants of CYP3A5, CYP2D6, SULT1A1, UGT2B15 and tamoxifen response in postmenopausal patients with breast cancer.
    Wegman P; Elingarami S; Carstensen J; Stål O; Nordenskjöld B; Wingren S
    Breast Cancer Res; 2007; 9(1):R7. PubMed ID: 17244352
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discriminative quantification of cytochrome P4502D6 and 2D7/8 pseudogene expression by TaqMan real-time reverse transcriptase polymerase chain reaction.
    Endrizzi K; Fischer J; Klein K; Schwab M; Nüssler A; Neuhaus P; Eichelbaum M; Zanger UM
    Anal Biochem; 2002 Jan; 300(2):121-31. PubMed ID: 11779102
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [CYP2D6 and GSTM1 genetic polymorphism and lung cancer susceptibility].
    Gao J; Ren C; Zhang Q
    Zhonghua Zhong Liu Za Zhi; 1998 May; 20(3):185-6. PubMed ID: 10921002
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human liver cytochrome P450 2D6 genotype, full-length messenger ribonucleic acid, and activity assessed with a novel cytochrome P450 2D6 substrate.
    McConnachie L; Bodor M; Kowdley K; Levy A; Tung B; Thummel K; Phillips B; Bajpai M; Chi V; Esmay JD; Shen DD; Ho RJ
    Clin Pharmacol Ther; 2004 Apr; 75(4):282-97. PubMed ID: 15060507
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Combined effects of genetic polymorphisms in cytochrome P450s and GSTM1 on lung cancer susceptibility].
    Gu YF; Zhang ZD; Zhang SC; Zheng SH; Jia HY; Gu SX
    Zhonghua Yi Xue Za Zhi; 2007 Nov; 87(43):3064-8. PubMed ID: 18261353
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Functional characterization of 17 CYP2D6 allelic variants (CYP2D6.2, 10, 14A-B, 18, 27, 36, 39, 47-51, 53-55, and 57).
    Sakuyama K; Sasaki T; Ujiie S; Obata K; Mizugaki M; Ishikawa M; Hiratsuka M
    Drug Metab Dispos; 2008 Dec; 36(12):2460-7. PubMed ID: 18784265
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetic polymorphism of CYP2D6 and lung cancer risk.
    Shaw GL; Falk RT; Frame JN; Weiffenbach B; Nesbitt JC; Pass HI; Caporaso NE; Moir DT; Tucker MA
    Cancer Epidemiol Biomarkers Prev; 1998 Mar; 7(3):215-9. PubMed ID: 9521436
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Only truncated, not complete cytochrome p450 2D6 RNA transcript and no detectable enzyme activity are expressed in human lymphocytes.
    McConnachie LA; Phillips B; Bajpai M; Shen DD; Ho RJ
    Drug Metab Dispos; 2003 Sep; 31(9):1103-7. PubMed ID: 12920165
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Functional analysis of CYP2D6.31 variant: homology modeling suggests possible disruption of redox partner interaction by Arg440His substitution.
    Allorge D; Bréant D; Harlow J; Chowdry J; Lo-Guidice JM; Chevalier D; Cauffiez C; Lhermitte M; Blaney FE; Tucker GT; Broly F; Ellis SW
    Proteins; 2005 May; 59(2):339-46. PubMed ID: 15726636
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibitory effect of rifampicin on the depressive action of interleukin-1 on cytochrome P-450-linked monooxygenase system.
    Kurokohchi K; Yoneyama H; Nishioka M; Ichikawa Y
    Metabolism; 2001 Feb; 50(2):231-6. PubMed ID: 11229434
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The importance of heterogeneous nuclear ribonucleoprotein K on cytochrome P450 2D2 gene regulation: its binding is reduced in Dark Agouti rats.
    Sakai N; Sakamoto KQ; Fujita S; Ishizuka M
    Drug Metab Dispos; 2009 Aug; 37(8):1703-10. PubMed ID: 19420131
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular cloning, expression, and characterization of CYP2D17 from cynomolgus monkey liver.
    Mankowski DC; Laddison KJ; Christopherson PA; Ekins S; Tweedie DJ; Lawton MP
    Arch Biochem Biophys; 1999 Dec; 372(1):189-96. PubMed ID: 10562433
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Folylpoly-gamma-glutamate synthetase gene mRNA splice variants and protein expression in primary human leukemia cells, cell lines, and normal human tissues.
    Leclerc GJ; Barredo JC
    Clin Cancer Res; 2001 Apr; 7(4):942-51. PubMed ID: 11309345
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetic variability in cytochrome P450 3A5 and in vivo cytochrome P450 3A activity: some answers but still questions.
    Wilkinson GR
    Clin Pharmacol Ther; 2004 Aug; 76(2):99-103. PubMed ID: 15289786
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.